Three researchers from the Garvan Institute of Medical Research have received fellowships from Cancer Institute NSW to support their investigations into new therapeutic strategies for cancer. Dr Angela Chou was awarded an Early Career Fellowship. She is researching a new targeted drug in pancreatic cancer which, in initial preclinical testing, showed promise in a subgroup of tumour cells with specific genetic traits. Dr Chou plans to test this drug in a newly established model of invasive pancreatic cancer, and to explore its combination with different chemotherapies currently in clinical use, with the future aim of improving response and survival in pancreatic cancer patients. Dr David Gallego-Ortega received a Career Development Fellowship to support his work, which focuses on making immunotherapies an effective treatment for breast cancer. Immunotherapies work by “re-educating” the immune system to recognise and combat cancer cells. In breast cancers, however, the immune system’s function is “dialled down” and immunotherapies can’t work effectively. Dr Gallego-Ortega’s work will use state-of-the-art technology at single-cell level to investigate how this happens, and how to reverse it, so that the immune system can effectively target breast cancer cells. Dr Marina Pajic was awarded a Career Development Fellowship. Dr Pajic’s previous genomic analyses of pancreatic tumours identified a number of new genetic drivers of pancreatic cancer and this funding will support the preclinical assessment of several new drugs that individually target these drivers. A key aim of Dr Pajic’s work is to develop a more efficient strategy for the testing of new therapeutics that will accelerate progress into clinical trials, and ultimately lead to personalised therapy for pancreatic cancer patients.
Dr Anne Bruestle, from the John Curtin School of Medical Research at the ANU, has been awarded the Gordon Ada Early Career Researcher Award, and has presented the Gordon Ada Oration: Th17 cells in neuro inflammation: What we can learn from animal models of multiple sclerosis. The annual award, established in 2012 in honour of Emeritus Professor Gordon Ada, recognises early career researchers at JCSMR who have made major contributions to biomedical research. Awardees receive $1000 and are invited to present their work as the annual Gordon Ada Oration. The award capped a good month for Dr Bruestle who earlier was awarded $200 000 from MS Research Australia to develop new techniques to treat multiple sclerosis. The new project will look at how different immune cells interact with neutrophils, a type of immune cell that can combat infection by expelling their DNA to kill bacteria. The process known as neutrophil extracellular traps or NETs forms an important part of the body’s defence against infection. NETs can also mistakenly kill the body’s own cells, leading to a variety of diseases. Dr Bruestle said her team will look at how NETs induce neuronal inflammation and how new drugs could inhibit the process. The final stage of the project aim is to take the laboratory findings to patients and examine the level of neutrophils and NETs in the blood of people with MS.
Associate Professor Peter Stanwell, from the University of Newcastle, has been awarded a Fulbright Professional Scholarship. With a 20+ year history in magnetic resonance imaging (MRI), A/Professor Stanwell will use his Fulbright Scholarship to explore the underlying changes that occur in the brain after traumatic brain injury, and how these changes predispose some individuals to later-life cognitive deterioration and neurodegeneration. There is concern amongst health care professionals that milder forms of repetitive brain injury may have long term adverse effects on cognition and development of dementia in later, adult life in high risk groups. A/Professor Stanwell’s recent work combining CLARITY light sheet microscopy and advanced MRI techniques has explored ultrastructural changes that occur following brain injury. Working with global experts in advanced MRI imaging and analysis and light sheet fluorescence microscopy, he will build on this preliminary work and help researchers gain new insights in this area. As well, he hopes to identify evidence-based MRI biomarkers to optimise medical treatment of patients following traumatic brain injuries. A/Professor Stanwell will work with A/Professor Alex Lin at Brigham and Women’s Hospital, and Dr Susan Whitfield-Gabrielli at the McGovern Institute for Brain Research at MIT to achieve these goals.
Professor Peter Macdonald from the Victor Chang Institute has been honoured with the NSW Ministerial Award for Cardiovascular Research Excellence for his significant contribution to improving treatment for heart failure, in particular, identifying strategies to minimise donor heart injury, reduce transplant allograft rejection and increase awareness of organ donation. He also commits his time to his translational research laboratory for testing new strategies for mechanical assistance for patients awaiting transplantation and identifying procedures for minimising donor heart injury. Also from the Victor Chang Institute, Dr Joshua Ho has been awarded the NSW Ministerial Award for a Rising Star in Cardiovascular Research. Dr Ho is a computational biologist who has already made significant contributions to biomedical research. In his very short career to date, he has already made a great contribution to mentoring of four current PhD students and two Honours students. Dr Ho has also made significant contributions to strengthening bioinformatics research locally as a founding member of the Australian Bioinformatics and Computational Biology Society (2014) and through his organisation of workshops and conferences.
Professor Garry Jennings AO has been named as the new Executive Director of Sydney Health Partners, an advanced health research and translation centre, made up of Sydney, Northern Sydney and Western Sydney Local Health Districts; the Sydney Children’s Hospitals Network (Westmead); the University of Sydney; and nine affiliated independent medical research institutes, including the Children’s Medical Research Institute. Professor Jennings served as the director of Baker IDI Heart and Diabetes Institute in Melbourne for 14 years and most recently as the interim CEO of the National Heart Foundation. He has had a long association with the National Heart Foundation as a former board Member and chair of its Cardiovascular Health Advisory Committee. He will also remain active in his clinical and research activities. As a leading cardiologist, Professor Jennings has also had a long career in clinical practice including as the director of Cardiology at The Alfred Hospital, Melbourne. Professor Jennings also played a key role in the transformation of The Alfred campus as Foundation Chair of the Alfred Medical Research and Education Precinct.
Funded by the Mark Hughes Foundation (MHF), radiation oncologist Dr Mike Fay from the University of Newcastle has been named the inaugural recipient of a 3-year Hunter Medical Research Institute Mid-Career Research Fellowship dedicated to brain cancer. As a clinical expert in advanced imaging for brain tumours, Dr Fay’s research is developing scanning markers and targeted therapies for cancer cells that resist current treatments. Having trained in medical oncology before changing to radiation oncology, Dr Fay has worked in more than 30 hospitals across five countries, including the US and Germany. His research interests were sparked by a study aimed at predicting toxicity from radiotherapy – his paper won a prize from the Royal Australian and New Zealand College of Radiologists and was published in the International Journal of Radiation Oncology Biology and Physics. Along with collaborators, Dr Fay is studying high grade brain tumours that have oxygen-deprived (hypoxic) regions requiring three times as much radiation dose to treat. He believes that critical factors to treatment resistance will be found there.
Wesley Medical Research has awarded 10 researchers specialising in the treatment and management of neurological diseases for their contribution to improving the care and quality of life of patients. The neuroscientists were awarded for researching new therapies and management techniques that may slow the progression of neurological diseases. Emeritus Professor Mervyn Eadie AO was presented with a Lifetime Achievement award for his work for over 50 years on the treatment of conditions like epilepsy and migraines. Dr Susanna Mantovani, who was recognised as one of the Emerging Leaders in Neurology Research, is comparing the sleep patterns of neurodegenerative patients with the healthy population to find ways to slow the progression of neurological diseases like motor neurone disease. Senior Research Fellowships were awarded to Professor Pamela McCombe, Professor John O’Sullivan, Professor Rob Henderson and Dr Noel Saines. Dr Richard Gordon, Dr Trent Woodruff, Dr Shyuan Ngo and Dr Frederik Steyn were awarded as Emerging Leaders in Neurology Research.
Doherty Institute postdoctoral scientist Dr Amy Chung is one of six recipients internationally and the only Australian, to be awarded a prestigious Mathilde Krim Fellowship in Basic Biomedical Research for her HIV vaccine research. The fellowships are presented annually by The Foundation for AIDS Research (amfAR), in honour of the organisation’s founding chairman, Dr Mathilde Krim, to support bright young scientists seeking innovative solutions to HIV and AIDS. Based at the University of Melbourne in Professor Stephen Kent’s laboratory, Dr Chung will use her Krim Fellowship, USD$150 000 over 2 years, to study the mechanisms by which different types of antibodies interact, with the aim of producing an effective HIV vaccine.
Professor Julie Quinlivan, a practising gynaecologist and obstetrician, and professor of medicine at the University of Notre Dame, has been appointed as the Director of the Professional Services Review (PSR), for the next 3 years. The PSR is an independent statutory authority that investigates whether health practitioners have provided inappropriate services that attract benefits under the Medicare Benefits Scheme. It also looks at whether medicines have been inappropriately prescribed under the Pharmaceutical Benefits Scheme. In doing so, the PSR plays an integral role in the regulatory framework of Australia’s health care system, to protect the integrity of both schemes. The Australian Medical Association has endorsed Professor Quinlivan’s appointment.
The University of Queensland’s new Centre for the Business and Economics of Health has opened its doors. Acting director, Professor Luke Connelly said the centre will lead research into cost-effective health care solutions, and connect researchers and resources from UQ’s Faculty of Business, Economics and Law, Faculty of Health and Behavioural Sciences, Mater Health Services and the Mater Research Institute. A donation from two UQ alumni – Fidelity Worldwide Investments Head of Australian Equities Paul Taylor and his wife Sue – kick-started the centre in 2016.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.